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HIGHLIGHTS 
 Chitosan nanoparticles (CSNPs) were prepared through crosslinking with 
tripolyphosphate salts  
 Magnetic nanoparticles and 5-fluorouracyl (5-FU) were encapsulated within 
CSNPs 
 5-FU release measured after 30 days decreases with magnetic nanoparticles 
content 
 CSNPs were successfully internalized over fibroblasts and A-172 cancer cells 
 CSNPs induced cell apoptosis by combination of magnetic hyperthermia and 
chemotherapy  
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ABSTRACT 
Chitosan nanoparticles (CSNPs) ionically crosslinked with tripolyphosphate salts (TPP) 
were employed as nanocarriers in combined drug delivery and magnetic hyperthermia 
(MH) therapy. To that aim, three different ferrofluid concentrations and a constant 5-
fluorouracil (5-FU) concentration were efficiently encapsulated to yield magnetic 
CSNPs with core-shell morphology. In vitro experiments using normal cells, fibroblasts 
(FHB) and cancer cells, human glioblastoma A-172, showed that CSNPs presented a 
dose-dependent cytotoxicity and that they were successfully uptaken into both cell lines. 
The application of a MH treatment in A-172 cells resulted in a cell viability of 67-75% 
whereas no significant reduction of cell viability was observed for FHB. However, the 
A-172 cells showed re-growth populations 4 hours after the application of the MH 
treatment when CSNPs were loaded only with ferrofluid. Finally, a combined effect of 
MH and 5-FU release was observed with the application of a second MH treatment for 
CSNPs exhibiting a lower amount of released 5-FU. This result demonstrates the 
potential of CSNPs for the improvement of MH therapies.  
KEYWORDS: chitosan, magnetic nanoparticles, drug delivery, cytotoxicity, uptake, 
magnetic hyperthermia, cancer cells, in vitro studies 
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1. Introduction  
Chitosan (CS) is a natural polymer obtained from extensive deacetylation of 
chitin, the second most abundant polysaccharide on earth after cellulose. It is mainly 
composed of two kinds of structural units: 2-amino-2-deoxy-d-glucose and N-acetyl-2-
amino-2-deoxy-d-glucose linked by a β(1 → 4) bond. Chemical modification via its 
amino or primary and secondary hydroxyl groups results in molecular structures with 
additional functionalities (C. Peniche, F.M. Goycoolea & Argüelles-Monal, 2008 ; 
Fernández-Quiroz et al., 2015). Chitosan is inherently biodegradable and biocompatible 
and it has attracted a lot of attention over the last few years for the development of 
biomedical applications. (Dash, Chiellini, Ottenbrite & Chiellini, 2011; de la Fuente, 
Raviña, Paolicelli, Sanchez, Seijo & Alonso, 2010; Muzzarelli & Muzzarelli, 2005). 
Among them, chitosan nanoparticles provide interesting opportunities as nanocarriers of 
antitumoral drugs employed for chemotherapy (Chen et al., 2014; Deng, Zhen, Hu, Wu, 
Xu & Chu, 2011; Lozano, Torrecilla, Torres, Vidal, Domínguez & Alonso, 2008; 
Unsoy, Khodadust, Yalcin, Mutlu & Gunduz, 2014). Chemotherapy can be combined 
with other cancer treatments in order to induce a higher efficacy in the treatment by 
producing a synergistic therapeutic effect and improving tumor regression(Hervault & 
Thanh, 2014; Kumar & Mohammad, 2011; Mignani, Bryszewska, Klajnert-
Maculewicz, Zablocka & Majoral, 2015). In this sense, some studies employing 
chitosan as main polymer have been reported, as an example, polymer nanoparticles 
prepared from partially quaternized derivatives of chitosan have been employed for 
combined cancer treatments based on gene therapy and drug release of paclitaxel. These 
nanoparticles were capable of improving the intestinal absorption, enhance cellular 
uptake, and avoid lysosomal entrapment (Wei et al., 2013) 
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Hyperthermia is another clinical therapy used concurrently with chemotherapy 
to achieve a synergistic effect for the combined treatment(Huang, Neoh, Xu, Kang & 
Chiong, 2012). The basis of the hyperthermia protocol is to increase the temperature of 
target cells to 41-46 ºC to impair the cell’s repair mechanisms.(Jordan, Scholz, Wust, 
Fähling & Roland, 1999; Laurent, Dutz, Häfeli & Mahmoudi, 2011) Recently, the use 
of magnetic nanoparticles (mainly magnetite, Fe3O4) as heating agents has been 
approved for clinical uses, originating a new therapy called magnetic hyperthermia 
(MH). The heating during MH is based on the energy absorbed by the magnetic 
nanoparticles under irradiation with a low-frequency (i.e., 100 kHz – 900 kHz) 
alternating magnetic field (AMF). The particles transform the energy of the magnetic 
field into heat by different physical mechanisms, and the transformation efficiency 
strongly depends on the nature of the particles such as particle size (Goya et al., 2008), 
agglomeration state (Gupta & Gupta, 2005) and viscosity of the surrounding medium. 
On the other hand, the application of a AMF to polymer drug carriers containing 
magnetic nanoparticles may accelerate the drug release rate as recently demonstrated for 
carboxymethyl chitosan and carrageenan beads (Mahdavinia, Etemadi & Soleymani, 
2015) or carboxymethyl dextran -coated magnetoliposomes (Guo, Chen, Sun, Liu, Li & 
Wang, 2015). This result has been attributed to the motion of the MNPs originated by 
the application of the AMF that leads to the relaxation of the polymer chains. 
There are few studies about CSNPs loaded with magnetic nanoparticles for 
hyperthermia applications. As example, Fe3O4-chitosan magnetic nanoparticles were 
obtained via suspension crosslinking method employing glutaraldehyde as the 
crosslinker and iron oxide nanoparticles obtained by coprecipitation. The application of 
an AMF gave rise to an increase of temperature measured in physiological saline 
suspensions (Zhao, Wang, Zeng, Xia & Tang, 2009). In another example,   iron oxide 
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magnetic particles were coated with chitosan by spray-drying method. The application 
of an alternating magnetic field gave rise to a temperature increase of 7 °C (from 25 °C 
to 32 °C) (Donadel, Felisberto, Fávere, Rigoni, Batistela & Laranjeira, 2008).  In a 
recent study, we demonstrated that the crosslinking reaction of chitosan with sodium 
tripolyphosphate (TPP) constitutes a mild and efficient method to encapsulate magnetic 
iron oxide nanoparticles (MNPs) giving rise to magnetic CSNPs with a core-shell 
morphology. Very importantly, aqueous dispersions of magnetic CSNPs undergo an 
increase of temperature when subjected to an alternating magnetic field ((f=580 kHz, 
H=24kA/m)(Zamora-Mora, Fernández-Gutiérrez, Román, Goya, Hernández & 
Mijangos, 2014).  
To the best of our knowledge, this is the first time that CSNPs are evaluated 
through in vitro studies for their application in a combined chemotherapy and magnetic 
hyperthermia therapy. To that aim, CSNPs were loaded with a model antitumoral drug, 
5-fluorouracil (5-FU) and MNPs. The 5-FU release from CSNPs loaded with different 
amounts of MNPs was evaluated at physiological temperature and pH. CSNPs were 
tested for their cytotoxicity and their in vitro magnetic hyperthermia performance after 
being internalized in connective cells (fibroblasts) and malignant human glioblastoma 
cells (A-172). The results obtained from the combined therapy, magnetic hyperthermia 
and chemotherapy, were compared to those obtained for CSNPs loaded with MNPs or 
5-FU separately in order to quantify the efficiency for each of the individual treatments.   
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2. Materials and methods 
2.1. Materials 
Chitosan employed in this work was isolated from shrimp's shell (Heterocarpus 
vicarious) and supplied by Polymers Laboratory, National University, Costa Rica. The 
degree of N-acetylation (DA= 0.12) chitosan was determined by 1H-NMR (Figure S1) 
according to the procedure described by  (Vårum, Antohonsen, Grasdalen & Smidsrød, 
1991). The molecular weight of 362 KDa was determined by the viscosity method 
(ASTM D 2857). Oleic-acid-coated magnetic iron oxide nanoparticles (MNPs) 
dispersed in water as ferrofluid (density =1.08 g/mL), were provided by Nanogap 
Subnmparticles, Spain. According to the manufacturer, the crystalline form of the iron 
oxide nanoparticles is magnetite, Fe3O4 and their average size is 18.55 ±2 nm. Milli-Q 
(18.3 MΩ) water was used in all experiments. The following chemicals were purchased 
from Sigma-Aldrich Company (St. Louis, MO, USA) and used as received: sodium 
tripolyphosphate (TPP), 5-Fluorouracil (5-FU) and phosphate buffered saline (PBS 
pH=7.4). 
2.2. Preparation of 5-fluorouracil (5-FU) and magnetic nanoparticles loaded chitosan 
nanoparticles  
A determined amount of pure ferrofluid was dispersed in 5 mL of milli-Q water 
to yield final ferrofluid concentrations of 5, 20 and 50 mg/mL. Each of these ferrofluid 
solutions were mixed under mechanical stirring in a N2 atmosphere with a chitosan 
solution (0.5% w/v) in a volumetric ratio chitosan: ferrofluid of 6:1. Separately, 5-
fluorouracil was dissolved in an aqueous solution of sodium tripolyphosphate (TPP) 
(0.5% w/v), to a final concentration of 0.5% (w/v). Then, 6 mL of the aqueous solution 
containing 5-FU and TPP was added dropwise into the aqueous solution containing 
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chitosan (30 mL) and ferrofluid (5 mL) under mechanical dispersion at 8600 rpm, 
followed by stirring for 10 min at room temperature. The 5-FU concentration was 
chosen based on the IC50 results obtained for 5-FU in FBH (24.06 mg/mL) and A-172 
cells (4.04 mg/mL) (results shown in supplementary information, figure S2). A 
concentration below IC50 is needed in order to ensure activity of the drug at non 
cytotoxic concentrations for the cells. CSNPs were collected by centrifugation at 5000 
rpm for 20 min. Finally, the supernatant was separated and then it was freeze-dried. 5-
FU and ferrofluid loaded chitosan NPs were named 5-FU-CS-MNPx, where x 
correspond to the Fe3O4-MNPs concentration. The Fe3O4-MNPs concentration in the 
CSNPs was determined by measuring their Fe contents through UV-VIS transmission 
spectrophotometry (Shimadzu UV-160), based on the thiocyanate complexation 
reaction(Gupta & Gupta, 2005):   
𝐹𝑒(𝑎𝑞)
3+ + 6 𝑆𝐶𝑁(𝑎𝑞)
−  →  ⌊𝐹𝑒(𝑆𝐶𝑁)6⌋(𝑎𝑞)
3−  
CSNPs were dissolved in HCl 6 M-HNO3 (65%) at 60 0C during 2 h. Potassium 
thiocyanate was then added to the Fe3+ solution to form the iron-thiocyanate complex, 
which has strong absorbance at 478 nm wavelength. The iron concentration was 
determined by comparing the sample absorbance to a calibration curve. For each of the 
initial concentrations of ferrofluid employed in the preparation of CSNPs (5, 20 and 50 
mg/mL), the final MNPs concentration achieved was 1, 3.2 and 5.6 mg/mL.  
As a control material, chitosan NPs loaded only with MNPs were prepared 
following a method reported elsewhere (Zamora-Mora, Fernández-Gutiérrez, Román, 
Goya, Hernández & Mijangos, 2014). Sample was denoted as CS-MNP5.6 where the 
number refers to the iron concentration determined by UV-vis spectroscopy. A second 
control sample was prepared by encapsulation of only 5-FU and named 5-FU-CS-NPs. 
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5-FU-CS-NPs were obtained by dropwise addition of an aqueous solution containing 
TPP and 5-FU into a chitosan stock solution (0.5% w/v) in a ratio chitosan: TPP+5-FU 
of 5:1, under mechanical stirring (8600 rpm) at room temperature. The resulting 
aqueous dispersion of 5-FU-CS-NPs was centrifuged at 5000 rpm during 20 min 
(centrifuge Sigma 2-16P). The precipitate was discarded and the supernatant fraction 
was subjected to freeze-drying. 
2.3. Physicochemical and morphological characterization 
Micrographs of the samples were taken using a field emission scanning electron 
microscope (FESEM) Hitachi model SU8000 HRSEM (Hitachi High-Technologies 
Corporation, Tokyo, Japan) used in the TE (electron transmission) detector bright field 
mode. For visualization of CSNPs by FESEM, one drop of aqueous dispersions of the 
samples was deposited on the Formvar-carbon-coated Cu grid.  
Dynamic Light Scattering (DLS) was used for the determination of the CSNPs 
hydrodynamic diameter and potential employing a Malvern Nanosizer Nazo ZS 
(Malvern Instruments Ltd, United Kingdom) with a 633 nm laser diode and a 
backscattering detection angle of 173º. Samples were dispersed in milli-Q water at 25 
°C and the resulting pH of the dispersions was 4.5. The electrophoretic mobility was 
transformed into potential employing the Smoluchowski equation. All measurements 
were repeated three times and the average of three runs was taken as the result. 
Attenuated Total Reflection Fourier Transformed Infrared Spectroscopy (ATR-
FTIR) was carried out on freeze-dried samples. Spectra were measured in a Spectrum 
One FT-IR Spectrometer of Perkin Elmer (PerkinElmer Life and Analytical Sciences, 
USA) in the wave number range of 650-4000 cm−1 and with 4 cm−1 resolution. 
2.4. Evaluation of drug encapsulation efficiency and loading efficiency.  
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For the determination of encapsulation efficiency (EE) of 5-FU within CSNPs, 
samples were centrifuged at 12000 rpm for 30 min, using centrifuge tubes IVSS 
Vivaspin 20, with a pore size of 3000 MWCO, to recover the residual fraction 
containing the 5-FU free. Then, this fraction was measured by ultraviolet spectroscopy 
(Perkin Elmer Instrument Lambda 35 UV/VIS spectrometer). 5-FU was measured at 
265 nm where an intense characteristic peak was displayed. The encapsulation 
efficiency was calculated according to the following equation (Papadimitriou, Bikiaris, 
Avgoustakis, Karavas & Georgarakis, 2008): 
𝐸𝐸 =  (
(𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 5−𝐹𝑈) − (𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑓𝑟𝑒𝑒 5−𝐹𝑈) 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 5−𝐹𝑈
)  𝑥 100     Equation 1 
The loading efficiency of 5-FU loaded into 5-FU-CS-NPs and 5-FU-CS-MNPs 
samples was determined from the freeze-dried samples as follows: a known weight of 
freeze-dried samples was dissolved in acetic acid (1% v/v). Then the drug content was 
analyzed using UV/Vis spectroscopy at 265 nm with the appropriate dilutions. The 
loading efficiency (LE) was calculated as follows: 
𝐿𝐸 =  (
(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 5−𝐹𝑈 𝑖𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑒𝑑 𝑖𝑛𝑡𝑜 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠)
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑟𝑒𝑒𝑧𝑒−𝑑𝑟𝑖𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
)  𝑥 100  Equation 2 
All measurements were performed in triplicate and the mean value calculated.  
2.5. Evaluation of in vitro drug release. 
The release of 5-FU from CSNPs was studied at physiological pH, according to 
the protocol of Zhu and coworkers (Zhu, Ma, Jia, Zhao & Shen, 2009) with some 
modifications. Each of the samples under study was dispersed to a concentration of 
0.01% (w/v) in phosphate buffer solution (pH=7.4). Then, 3 mL of each dispersion was 
placed into a dialysis tubing (MWCO 3500-5000 Da) that was immersed in 10 mL of 
the buffer at 37 ºC with moderate orbital stirring. An aliquot of 1 mL was withdrawn 
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from the release medium at regular times and replaced with equivalent aliquots of fresh 
medium during 30 days. The kinetics of release of 5-FU from 5-FU-CS-NPs and 5-FU-
CS-MNPs was measured by UV/Vis spectroscopy (Perkin Elmer Instrument Lambda 35 
UV/VIS spectrometer, at 265 nm). All data reported are an average of three 
measurements.    
2.6. Cytotoxicity study by Alamar Blue assay  
The cytotoxicity of the 5-FU-CS-NPs and three 5-FU-CS-MNPs was measured through 
Alamar Blue (Mignani, Bryszewska, Klajnert-Maculewicz, Zablocka & Majoral) 
(provided by Serotec, Spain) assays for two cell lines, human dermal fibroblast (FBH-
INNOPROT SPAIN) and malignant human glioblastoma cells (A-172-ECACC, UK). 
Samples were sterilized with a UV lamp (HNS OSRAM, 263 nm, 3.6UVC/W) at a 
power of 11 W for 2 h. Both cell lines were seeded into 96 wells plates at a density of 1 
× 105 cells/mL (1 × 104  cells/well)  in complete medium and incubated to confluence. 
After being cultured for 24 h, FBH and A-172 cells were treated with different aqueous 
dispersions of 5-FU-CS-NPs and 5-FU-CS-MNPs and incubated at 37 ºC in humidified 
air (95%) with 5% CO2 for 24 h. After that, a solution of AB (10% v/v) prepared in a 
warm medium without phenol red was added to the plate and incubated at 37ºC for 4 h. 
Finally, fluorescence was measured with a Biotek Synergy HT detector using an 
emission wavelength of 590 nm and an excitation wavelength of 530 nm.  
Cell viability (CV) was calculated with the following equation:  
𝐶𝑉 =  100 × (
𝐹𝐷𝑠 – 𝐹𝐷𝐵
𝐹𝐷𝐶− 𝐹𝐷𝐵
)           Equation 3 
where FDS, FDB, and FDC are the fluorescence density of the AB for the sample (S), 
blank (B) (culture medium without cells), and control (C), respectively.  
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2.7      Cellular uptake of chitosan nanoparticles 
The cellular uptake of CSNPs was determined by epifluorescent microscopy, 
which is a method that allows observing the nanoparticles carrying a fluorescent label 
(sodium fluorescein dye 20%) in different cell lines (FBH and A-172). The experiment 
was as follows: a dispersion of fluorescent nanoparticles (0.06% (w/v) in medium 
without phenol red + fluorescein 0.01% v/v) was added to the cells seeded onto a glass 
dish in semi-confluence and incubated during 24 h at 37 ºC and 5% of CO2. The cells 
were rinsed with phosphate buffered saline (PBS) and fixed with paraformaldehyde 
3.7% in PBS for 10 min at 37 ºC. After that, paraformaldehyde was removed and cells 
were rinsed again with PBS. Finally, triton (Triton X-100, molecular biology grade, 
density 1.07 g/cm³) 0.05% (v/v) in PBS was added during 20 min at 37 ºC for 
permeability in the cellular membrane. The samples were rinsed with PBS and the cell 
nuclei were stained with 10 µL/mL of Hoechst H33342 dye solution. In addition, 
phalloidin (1 µL/ 100 µL) was used for staining the actin cytoskeleton of the cells and 
left it for 30 min at room temperature in the darkness. Finally, fluorescence was 
observed with an epifluorescence microscope (Nikon eclipse TE2000-S) and three 
different filters.  
2.8. In vitro magnetic hyperthermia experiments  
The magnetic hyperthermia experiments were performed using a commercial 10-
kW induction heating system (EASYHEAT, Ambrell, UK) using a 9-turn coil of 5 cm 
diameter specifically designed to accommodate a 3.5 cm petri dish inside. The samples 
were thermally insulated from the coil by a water-refrigerated jacket. The alternating 
magnetic field (f = 180 kHz; H = 35 kA/m) was applied during 20 min to the cells in the 
petri dish, and after that the cell viability of the two cell lines (i.e., malignant human 
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glioblastoma (A-172) and fibroblast (FBH)) loaded with CSNPs was measured. A 
scheme of the experiment is shown in the supplementary information (Figure S3). Both 
cell lines (FBH and A-172) were seeded separately onto an Ibidi dish (µ-Dish 35 mm, 
sterile, low wall) at a density of 15 × 104 cells/mL in complete medium and incubated to 
confluence. After being cultured for 24 h, FBH and A-172 Ibidi dishes were treated 
with the corresponding dispersion of nanoparticles. Finally, after 24 h of incubation 
samples were exposed to the AC field during 20 min. After that, the samples were 
rinsed with PBS to remove dead cells and free CSNPs. Samples were fixed with 
glutaraldehyde 2.5% (v/v) at 37 °C after two different times, 10 min and 4 hours after 
the MH treatment (1MH). A second magnetic hyperthermia treatment (2 MH) was 
applied to A-172 cells and samples were fixed 4 h later. Crystal violet staining was used 
for determining cell viability. All the samples fixed, were treated with a 0.1% (w/v) of 
aqueous solution of crystal violet in PBS pH 7.2. After 10 min of incubation at room 
temperature under agitation, the staining solution was discarded; the samples were 
washed with Milli-Q water and then dried at 37 ºC. Finally, aqueous acetic acid (10% 
v/v) was added to the samples and an aliquot of 200 µL was taken and placed into a 
well of plates to determinate the relative viability by a microplate reader at 620 nm-690 
nm.  
All the samples after the cell fixation were treated with acridine orange and 
propidium iodide (AO/PI), to visualize living and dead cells simultaneously. Acridine 
orange (AO) is permeable to both live and dead cells and stains all nucleated cells to 
generate green fluorescence. On the other hand, propidium iodide (PI) enters dead cells 
with compromised membranes and stains all dead nucleated cells to generate red 
fluorescence. The procedure was as follows: all the samples fixed after magnetic 
hyperthermia treatment were rinsed with PBS and then triton (Triton X-100, molecular 
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biology grade, density 1.07 g/cm³) 0.05% (v/v) in PBS was added and the sample was 
maintained during 20 min at 37 ºC under low speed orbital shaking. After that, the 
samples were rinsed with PBS and 10 µL/mL of AO/PI staining solution was added and 
left it for 30 min at room temperature in the darkness. Finally, the samples were rinsed 
twice with Tween 20 solution at 0.1% in PBS and left it with Milli-Q water. Samples 
were observed in an epifluorescence microscope (Nikon eclipse TE2000-S) equipped 
with a FX-RED filter set to detect dead cells, and a FITC filter set to detect live cells. 
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3. Results and discussion  
3.1 Physicochemical and morphological characterization 
CSNPs loaded with 5-FU and MNP were successfully obtained by ionotropic 
coupling with TPP and it was corroborated by FESEM. The obtained nanoparticles are 
stable in the medium thanks to the ionotropic crosslinking of phosphate negative groups 
and free amine functions of the chitosan polymer chains(Fernandes, de Oliveira, 
Fatibello-Filho, Spinelli & Vieira, 2008; Yang et al., 2009). Figure 1 shows a 
representative FESEM image corresponding to sample 5-FU-CS-MNP3.2, in which it is 
possible to observe nanoparticles with particle size of 125±44 nm and a relatively high 
polydispersity which might be attributed to the method of preparation employed. 
Further information on the morphology obtained for the samples spread and dried on a 
glass surface can be obtained from atomic force microscopy images shown in figure S4.  
 
 
The hydrodynamic diameter and potential of the CSNPs determined through 
DLS measurements is reported in table 1. As can be observed, the hydrodynamic 
diameter increases with the MNPs encapsulation from 183±2 nm in the sample 5-FU-
CS-NPs to 255±9 nm in the sample 5-FU-CS-MNP5.6. Previous studies carried out on 
CSNPs loaded only with MNPs showed that the hydrodynamic diameter increased with 
the MNPs content. This was attributed to the fact that magnetite nanoparticles are 
subjected to Van der Waals forces and magnetic dipole-dipole interactions generated 
from residual magnetic moments that together may produce and increase in the particle 
size(Zamora-Mora, Fernández-Gutiérrez, Román, Goya, Hernández & Mijangos, 2014).  
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The ξ -potential, which is the electrostatic potential that exists at the shear plane 
of a particle, is related to both surface charge and the local environment of the particle 
(Rescignano et al., 2015). As previously reported, CSNPs crosslinked with TPP present 
a ξ-potential of +63.4±0.8 mV whereas commercial ferrofluid present a potential of -
75.8±3.2 mV(Zamora-Mora, Fernández-Gutiérrez, Román, Goya, Hernández & 
Mijangos, 2014). As can be observed in table 1, the ξ-potential values found for CSNPs 
loaded with 5-FU and MNPs slightly decreases with respect to that found for CSNPs 
crosslinked with TPP (+63.4±0.8 nm) and remained positive in the range of +52-+59 
Mv. This is abscribed to the protonated chitosan ammonium groups in the acidic 
environment that resulted from the dispersion of the CSNPs in milli-Q water and 
suggests the efficient encapsulation of the ferrofluid within the chitosan NPs.  It is clear 
from these results that the ionotropic coupling allows the orientation of the more 
hydrophilic segments of the network structure, corresponding to sequences of 
glucosamine rings, forming a `shell´ structure of the nanoparticle which contributes to 
the high positive value of the potential. The MNPs interact with the polyphosphate-
amine groups in the inner core of the CSNPs and remains in this position because of the 
network structure and morphology of the whole system.  
 
Figure 2 shows the ATR-FTIR spectra corresponding to all the samples under 
study.  
The presence of a strong band located at 1246 cm-1 which is attributed to C-F of 
5-FU ring(Zhu, Ma, Jia, Zhao & Shen, 2009) in the spectra corresponding to CSNPs, 
confirms the encapsulation of 5-FU. The band located at 804 cm-1 in the spectra of 5-FU 
(figure 2a), attributed to C-H out of plane deformation of 5-FU ring, shifts to higher 
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wavenumbers in the samples containing 5-FU (figure 2b-d). These shifts suggest the 
presence of dipolar interactions between the polymer matrix and 5-FU. The spectrum 
corresponding to chitosan (figure 2-f) presents characteristic vibrational absorption 
bands located at 1652 cm-1 that corresponds to the amide I vibration (labelled as I in 
figure 2f) and at 1593 cm-1 corresponding to the N-H bending vibration overlapping the 
amide II vibration (labelled as II in figure 2f)(Lawrie et al., 2007). As can be observed, 
the position corresponding to band I in CSNPs containing 5-FU and MNPs does not 
change with respect to chitosan. In contrast, the band II located at 1597 cm-1 shifts to 
1551 cm-1 in the ATR-FTIR spectrum corresponding to 5-FU-CS-NPs and to 1557 cm-1 
in the ATR-FTIR spectrum corresponding to 5-FU-CS-MNP5.6. The larger shifts 
observed for samples loaded with MNPs suggest an additional interaction between them 
and 5-FU that will be corroborated by the results obtained from in vitro drug release 
experiments shown in the next section.  
3.2 In vitro drug release 
The encapsulation efficiency (EE) and loading efficiency (LE) of 5-FU within 
CSNPs was determined through UV-spectroscopy. All the samples presented very 
similar encapsulation efficiencies with values in the range 80-82%. These results agree 
with other investigations which report EE on the range of 80-85%(Wang, Zeng, Tu & 
Zhao, 2013). On the other hand, LE values obtained for all the samples are on the range 
33-35%. According to the stoichiometry of the formulation, theoretically a LE of 20% 
should be obtained. The experimental difference is attributed to the fact that the partial 
precipitation of chitosan nanoparticles during the process of washing after their 
preparation modifies the real total amount of the isolated dried sample and, according to 
equation 2, this yields a higher value of the LE with respect to the expected value.   
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The accumulative release profiles of the 5-FU chemotherapeutic agent measured 
at normal physiological pH and temperature are shown in Figure 3. After 30 days, the 
sample 5-FU-CS-NPs presents the highest % cumulative 5-FU release (45±4). Samples 
5-FU-CS-MNP1 and 5-FU-CS-MNP3.2 present similar % cumulative 5-FU release 
after 30 days (30±3), however, for the sample with the highest content of MNPs 5-FU-
CS-MNP5.6, the % cumulative 5-FU release sharply decreases to 15±1. This result can 
be attributed to the interaction established between 5-FU and the MNPs as determined 
through ATR-FTIR so that drug diffusion can be considered as controlled and 
modulated by the coupled system.  
 
In addition, a close examination of the data plotted in figure 3 allows to observe 
that, for 5-FU-CS-MNP5.6, the % cumulative 5-FU release reaches a plateau after 2.5 
days, whereas for the rest of the samples, it takes 4 days to attain a plateau in the % drug 
cumulative release. In this case, the establishment of stronger interactions between the 
MNPs and the 5-FU as a consequence of the higher amount of MNPs of the sample 
might be responsible for the lower cumulative drug release obtained and, at the same 
time, promote a more sustained release of 5-FU.  
 
 
3.3 Cytotoxicity study 
The cytotoxicity of all the samples under investigation was evaluated with the 
Alamar Blue assay. The experiments were tested in two cell lines, fibroblasts (FBH) and 
malignant human glioblastoma cells (A-172). Both cell lines were treated with CSNPs 
dispersed at different concentrations in medium without phenol red. 
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Figure 4 shows that both cell lines presented a dose-dependent effect on the 
cellular viability for all the nanoparticles under study. That is, the higher the 
concentration of nanoparticles in the aqueous dispersions, the lower the cell viability.  
 
Specifically, CSNPs concentrations =5 mg/mL results in lower cell viability for 
normal cells, FBH with respect to cancer cells, A-172. This might be attributed to a 
higher resistance of cancer cells to the 5-FU treatment with respect to normal 
cells(Longley, Harkin & Johnston, 2003). This effect is also observed for FBH treated 
with 5-FU-CS-MNP5.6 (2.5 mg/mL) for which the cell viability decreases to 15% 
whereas for cancer cells, the cell viability is 60%.  Based on these results, we selected a 
concentration of 0.6 mg/mL of chitosan nanoparticles for the rest of the biological 
experiments which proved to be non-cytotoxic for any of the cell lines.  
3.4 Cellular uptake studies 
The cellular uptakes of the CSNPs under study in FBH and A-172 cells after 24 
h of incubation were measured through fluorescence technique using an epifluorescence 
microscope. Figure 5 shows fluorescence images corresponding to normal cells, FBH 
and cancer cells, A-172 incubated with sample 5-FU-CS-MNP5.6 for 24 h. To obtain a 
good observation of the fluorescence images, different dyes were used, 5-FU-CS-
MNP5.6 were stained with sodium fluorescein dye (green), the cellular nuclei were 
stained using a Hoechst H33342 dye solution (blue) and the cytoskeleton of the cells 
were stained using phalloidin (Donadel, Felisberto, Fávere, Rigoni, Batistela & 
Laranjeira). The merged image (union of the three stains) shows that after 24 h of 
incubation, 5-FU-CS-MNP5.6 nanoparticles were successfully internalized into normal 
cells, FBH (inset figure 5) and cancer cells, A-172 as denoted by the presence of yellow 
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dots that corresponds to some agglomeration of CSNPs around the cellular nuclei for 
both cases. Similar results were obtained for the rest of the CSNPs under study (results 
not shown).  Therefore, the results obtained show that the hydrodynamic diameter and 
potential of the three samples allows effective endocytosis into both cell lines.  
3.5 In vitro magnetic hyperthermia 
The effect of the applied magnetic field on the cell viability of FBH and A-172 
cells was determined from crystal violet staining experiments carried out on cell lines 
treated with aqueous dispersions of sample 5-FU-CS-MNP5.6 at a concentration of 0.6 
mg/mL (concentration determined from Alamar blue essays) and subjected to a single 
magnetic hyperthermia (1MH) treatment and two magnetic hyperthermia (2MH) 
treatments. The results obtained were compared to those corresponding to cells treated 
with chitosan NPs loaded with each of the therapeutic agents, 5-FU (5-FU-CS-NPs) and 
magnetic NPs (CS-MNP5.6) separately (Figure 6). 
As can be observed, FBH and A-172 cells show cellular damage after 1 MH 
treatment as evidenced by the small spots that correspond to dead or apoptotic cells. 
Moreover, important changes of cell morphology such as cell shrinkage, densification 
of the cytoplasm and a tighter packing of cell organelles were noticed. These changes in 
the morphology suggest that cells undergo an apoptotic process (Elmore, 2007).  
Despite the low concentration of chitosan NPs used in these experiments, it is clear that 
it was possible to induce cell death through the application of an alternating magnetic 
field on chitosan NP-loaded cells. It is important to mention that no temperature 
increase was observed during the MH experiments, as measured by an infrared 
thermographic camera (see supplementary information, figure S5). This was expected 
from the low average concentration of magnetic NPs within the cell culture, and also the 
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geometry of the experiment (i.e., a single layer of adherent cells in a petri dish) that 
allows a fast heat exchange through the surface of the cell culture. The observed 
decrease in cell viability due to alternating magnetic field in MNP-loaded cells has been 
previously reported by many authors, and attributed to specific intracellular damage 
provoked by the local effect of MNPs on subcellular units.(Creixell, Bohórquez, Torres-
Lugo & Rinaldi, 2011) (Villanueva et al., 2010) (Asin, Goya, Tres & Ibarra, 2013) 
(Hildebrandt et al., 2002),(Asin, Ibarra, Tres & Goya, 2012) However, the induced cell 
death observed in the present experiments could have been further promoted by the 
effects of the therapeutic drug loaded into the CSNPs. The application of a second MH 
treatment on A-172 cells induced further cellular damage so that cells looked smaller 
than cells subjected to 1 MH treatment and appeared as a round or oval mass. This 
effect was more evident for cells treated with 5-FU-CS-NPs and 5-FU-CS-MNP5.6. 
Interestingly, A-172 cells treated with CS-MNP5.6, showed cell regeneration after 2 
MH treatments as evidenced by the formation of long filopodia. 
The results corresponding to the cell viability of FBH and A-172 cells fixed 10 
minutes after the application of 1 MH treatment are depicted in figure 7a. As can be 
observed, there is a significant reduction of the cell viability as a function of cell type 
being malignant human glioblastoma (A-172) more sensitive to the MH treatment than 
normal cells (FBH). In fact, FBH treated with all the samples under study presented cell 
viabilities higher than ~94 %, confirming that the MH treatment does not have an 
important effect on these cells. On the contrary, A-172 treated with CSNPs presented an 
important decrease in the cell viability with respect to the control for the three samples 
under study. For A-172 treated with 5-FU-CS-NPs, the decrease in cell viability is due 
to the antitumoral effect of 5-FU 
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Interestingly, similar cell viability values were achieved for A-172 cells 
incubated with 5-FU-CS-MNP5.6 and CS-MNP5.6. For sample CS-MNP5.6, the 
decrease of cell viability can be abscribed to the effect of magnetic hyperthermia. In the 
case of sample 5-FU-CS-MNP5.6, it is important to take into account that the % 
cumulative 5-FU release is significantly lower than the corresponding to 5-FU-CS-NPs 
as shown in figure 3. Therefore, the application of 1 MH treatment combined with a 
lower dose of 5-FU allows for a decrease in cell viability similar to the one found for 
samples incubated with 5-FU-CS-NPs thus proving the effective combination of 
magnetic hyperthermia and drug delivery.  
In order to determine the ability of A-172 cells to regenerate after having been 
subjected to 1 MH treatment, the cell viability was compared for cells fixed 10 minutes 
and 4 hours after 1MH treatment. A-172 cells fixed 4 hours after the application of 
1MH treatment (figure 7b) show an increase in cell viability with respect to A-172 cells 
fixed 10 minutes after the application of 1MH treatment (figure 7a) for all the samples 
under study which evidences cell regeneration. In addition, cell viability was compared 
for A-172 cells subjected to one and two MH treatments (figure 7b). A-172 cells 
incubated with CS-MNP5.6 show an increase of cell viability after the application of 2 
MH treatments. This result could be attributed to the cell proliferation rate of A-172 
cells in the presence of CS-MNP5.6 which overcomes the cellular death and it also 
suggest that some of the cells damaged during the 1 MH treatment appear as ‘healthy’ 
cells after few hours (4 hours). As expected, A-172 cells treated with sample 5-FU-CS-
NPs, which did not contain magnetic nanoparticles, did not present a significant change 
in cell viability. In contrast, samples treated with 5-FU-CS-MNP5.6 presented a slight 
decrease in cell viability after 2 MH treatments compared to the cell viability found 
after 1 MH treatment. This result further confirms the combined effect of the 5-FU that 
22 
 
continues to be released during the period of the treatment, together with the application 
of magnetic hyperthermia.  The results found demonstrate that cells treated with CS-
MNP5.6 are able to regenerate after MH treatment and thus, a combination of 
chemotherapy and magnetic hyperthermia is needed to increase the efficacy of 
treatment.  
Fluorescence images allows to obtain further information on cell death of FBH 
and A-172 cells after having been subjected to 1 and 2 MH treatments. As shown in 
figure 8, AO/PI staining allows recognizing easily dead cells (red fluorescence), lived 
cells (green fluorescence) and cells in the process of death (orange fluorescence). The 
red fluorescence highly increases for A-172 cell lines with respect to fibroblast which 
indicates a higher number of dead cells in this case.  
Figure S6 in supplementary info shows representative photographs of A-172 
cells incubated with 5-FU-CS-NPs, obtained after AO/PI staining and crystal violet 
staining after having been subjected to 1MH treatment. A vacuolization process (circles) 
can be observed which is characterized by the appearance of empty bags into the 
cytoplasm, indicating that cells are in process death. All these bags are enclosed within 
an intact plasma membrane, which is an important feature for apoptosis Also, typical 
nuclei separation and chromatin condensation related with apoptosis was observed 
(Elmore, 2007). AO/PI staining, for A-172 cell treated with CSNPs subjected to 2 MH 
treatments show significant evidence of cellular death and cells in process of death, 
recognized by the orange cells which are more visible in photographs corresponding to 
cells treated with 5-FU-CS-NPs and 5-FU-CS-MNP5.6.  
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4. Conclusions 
We have succeeded in producing a responsive material based on ionotropic 
coupled chitosan nanoparticles loaded with 5-FU and magnetic iron oxide nanoparticles. 
The concurrency of a good encapsulation and loading efficiency of the CSNPs (within 
the 80-85% and 30-36% range, respectively) indicate the potential of these materials for 
therapeutic purposes. It was demonstrated that the drug delivery profile of 5-FU from 
CSNPs can be modulated as a function of the concentration of MNPs, so that a higher 
content leads to a lower 5-FU release from CSNPs at physiological pH. CSNPs were 
successfully internalized over normal cells (fibroblasts) and malignant human 
glioblastoma cells (A-172). A dose-dependent cytotoxic effect was found for both cell 
lines, with A-172 cells being more sensitive than fibroblasts to CSNPs loaded with 5-
FU and iron oxide nanoparticles. Magnetic hyperthermia treatment was applied over 
fibroblast and malignant human glioblastoma cells (A-172) treated with CSNPs. After 
MH treatment, the cell viability for A-172 cells was on the range of 67-75% whereas for 
fibroblasts the cell viability was higher than ~94%. Therefore, A-172 cells were more 
sensitive to MH treatment than fibroblasts. Nevertheless, A-172 cells are able to 
regenerate when samples are observed 4 h after the application of a MH treatment. The 
application of a second MH treatment combined with 5-FU action leads to a higher 
efficacy of treatment. In view of the results obtained, CSNPs loaded with 5-FU and 
ferrofluid, can be considered as potential nanocarriers after the optimization of the 
preparation conditions for combined drug delivery and hyperthermia application, 
achieving a reduction of cell viability and inducing apoptosis after MH treatment. 
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Figure 1. Representative FESEM image corresponding to sample 5-FU-CS-MNP3.2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. ATR-FTIR spectra of a)5-FU, b)5-FU-CS-MNP5.6 c) 5-FU-CS-MNP3.2  d) 
5-FU-CS-MNP1, e) 5-FU-CS-NPs and f) CS 
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Figure 3. In vitro release of 5-FU from CSNPs measured at pH=7.4, (■) 5-FU-CS-NPs, 
(■) 5-FU-CS-MNP1, (■) 5-FU-CS-MNP3.2 and (■) 5-FU-CS-MNP5.6.  
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Figure 4. Evaluation of cytotoxicity of CS nanoparticles under study on a) normal cells, 
FBH and b) cancer cells, A-172. % relative cell viability was measured using Alamar 
Blue assay. All the results are shown as mean n=4 ±S.D.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Uptake studies for 5-FU-CS-MNP5.6 after 24 h of incubation, for normal 
cells, FBH and cancer cells, A-172. For easier visualization of 5-FU-CS-MNP5.6 inside 
the cells, a magnification of the merged image corresponding to FBH has been added 
as inset.  
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Figure 6.  Photographs (10x) of crystal violet staining for FBH subjected to a) 1 MH 
treatment and A-172 cells subjected to b) 1MH and c) 2 MH treatments.   
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Figure 7. % Relative cell viability obtained from crystal violet staining experiments for 
a) FBH and A-172 cells incubated with CS-MNP5.6, 5-FU-CS-NPs and 5-FU-CS-
MNP5.6 fixed 10 minutes after 1MH treatment and b) A-172 cells fixed 4 hours after 1 
MH treatment and 2 MH treatments. 
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Figure 8. Fluorescence images obtained after AO/PI staining for FBH subjected to a) 1 
MH treatment and A-172 cells subjected to b) 1MH and c) 2 MH treatments.   
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Table 1. Hydrodynamic diameter (nm) and potential (mV) of CSNPs 
Sample 
Hydrodynamic diameter (nm) potential 
(mV) 
5-FU-CS-NPs 
183±2 +52.5±1.2 
5-FU-CS-MNP1 
191±6 +55.2±0.9 
5-FU-CS-MNP3.2 
215±7 +58.0±0.8 
5-FU-CS-MNP5.6 
255±9 +59.0±0.9 
 
 
